- Company
- Phase III clinical trial plan for Rimatil has been submitted
- by Nho, Byung Chul Jul 8, 2020 09:14am
- Chong Kun Dang added a clinical pipeline for COVID-19 treatment following Nafabeltan. On the 18th of last month, Chong Kun Dang began the development of a COVID-19 treatment (clinical phase II) for its anticoagulant and acute pancreatitis treatment drug Nafabeltan (Nafamostat) on the 18th of last month. It is estimated that the mechanis
- Company
- “Liver cancer option expands, but needs further evidence”
- by Eo, Yun-Ho Jul 8, 2020 05:38am
- When a new drug development in a specific area is sluggish, there are two prominent reasons why; either the disease area has low marketability or the drug development itself for the disease is very difficult. In the latter case, a new drug gets an obvious spotlight when it is released to the market. Liver cancer (hepatocellular carcinoma
- Policy
- 13 drugs were sold before patent termination
- by Lee, Tak-Sun Jul 8, 2020 05:37am
- Domestic pharmaceutical companies were caught largely on charges of sales before patent termination. These pharmaceutical companies reported to the MFDS that they would sell after the end of the patent at the time of the application, but the sale was made even before the end of the patent through reporting on supply. The industry believ
- InterView
- Post-corona KSC academic conference finds answer in hybrid
- by An, Kyung-Jin Jul 8, 2020 05:37am
- The Korean medical academy scene also took a hit from the novel coronavirus (COVID-19). Still not contained COVID-19 pandemic had affected the spring academic conference and other events, which left the academic event coordinators in a tight spot. So what is it like to have an academic conference in the day and age of ‘Post-coronaviru
- Company
- Pfizer seeks for coverage on EGFR TKI to launch this year
- by Eo, Yun-Ho Jul 7, 2020 06:13am
- Pfizer Pharmaceutical Korea is quickly taking steps to join the competition in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) market. According to the pharmaceutical industry sources, Pfizer is in process of listing EGFR TKI Vizimpro (dacomitinib) for healthcare reimbursement. Vizimpro took the pricing negoti
- Policy
- Ticagrelor Napadisylate by Chong Kun Dang was applied
- by Lee, Tak-Sun Jul 7, 2020 06:13am
- It has been shown that Chong Kun Dang developed a salted product of Ticagreler (Brilinta, AstraZeneca) and applied for permission to the MFDS. It is the first product to be approved as a Ticagrelor salt product. Anti-thrombotic agent, Ticagrelor, is a poorly soluble drug and is known to have poor solubility, so it has been noted whether sa
- Policy
- Daewoong's Camostat was approved for clinical trial phase II
- by Lee, Tak-Sun Jul 7, 2020 06:12am
- Daewoong has been approved for clinical trials in patients with mild and moderate COVID-19 as a drug with Camostat Mesilate used as a treatment for pancreatitis. The MFDS approved a plan for phase II clinical trial for 'DWJ1248', which Daewoong applied for on the 6th. DWJ1248 is known as Camostat Mesilate. Daewoong holds Foistar (Camost
- Policy
- Stepped drug pricing applied on maximum price as of Aug 1
- by Kim, Jung-Ju Jul 7, 2020 06:12am
- The Korean government unveiled the specified schedule and plan to apply stepped drug pricing system, also known as the upper limit price reevaluation on listed drug. Although the Regulatory Reform Committee ordered Ministry of Food and Drug Safety (MFDS) to drop the ‘1+3 joint bioequivalence test system’ from the revised ‘Regulation o
- Opinion
- [Reporter’sView] A good administrative move by government
- by Eo, Yun-Ho Jul 6, 2020 10:44am
- Korea’s Ministry of Health and Welfare (MOHW) withdrew the plan to apply the stepped drug pricing reduction on drugs transferred by business restructuring in just four months to reflect the pharmaceutical industry’s opinion. It was first announced in February, and the revision was updated in June. The industry has been in a chaos for a
- Policy
- Samsung Bioepis' Adalloce prefilled pen was approved
- by Lee, Tak-Sun Jul 6, 2020 06:15am
- Samsung Bioepis’ pen type product of Humira (Adalimumab) biosimilar named Adalloce has additionally approved in Korea It is evaluated as a product with improved convenience of administration than Adalloce PFS that was approved in September 2017. The MFDS approved Samsung Bioepis' Adalloce prefilled pen 40mg on the 3rd. This product is
